ASLAN Pharmaceuticals Ltd - ADR

NASDAQ:ASLN   3:41:36 PM EDT
0.40
+0.01 (+2.57%)
Earnings Announcements

Aslan Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results

Published: 03/25/2022 11:14 GMT
ASLAN Pharmaceuticals Ltd - ADR (ASLN) - Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update.
Aslan Pharmaceuticals Ltd - Qtrly Loss per Ordinary Share Basic and Diluted $0.03.
Aslan Pharmaceuticals Ltd - Qtrly Loss per Equivalent Ads Basic and Diluted $0.16.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.